INSM (Insmed) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INSM Insmed Inc INSM
69 GF Score
Price $120.00
GF Value $216.47
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insmed  (NAS:INSM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Insmed Cyclically Adjusted PB Ratio Related Terms


Insmed Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Insmed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Cyclically Adjusted PB Ratio Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.79 5.20 9.50 22.91 63.36

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.19 46.89 58.44 55.28 36.29

INSM vs BNTX, INCY, ROIV: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Insmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted PB Ratio falls into.


INSM
69GF Score
Insmed Inc INSM
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Insmed's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Insmed's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.47/333.9520*333.9520
=3.470

Current CPI (Jun. 2026) = 333.9520.

Insmed Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.520 241.428 4.869
201612 2.491 241.432 3.446
201703 1.960 243.801 2.685
201706 1.338 244.955 1.824
201709 5.502 246.819 7.444
201712 4.713 246.524 6.384
201803 5.675 249.554 7.594
201806 4.811 251.989 6.376
201809 3.780 252.439 5.001
201812 2.694 251.233 3.581
201903 1.858 254.202 2.441
201906 3.997 256.143 5.211
201909 3.404 256.759 4.427
201912 2.918 256.974 3.792
202003 2.300 258.115 2.976
202006 3.996 257.797 5.176
202009 3.507 260.280 4.500
202012 2.685 260.474 3.442
202103 1.952 264.877 2.461
202106 4.608 271.696 5.664
202109 4.265 274.310 5.192
202112 3.457 278.802 4.141
202203 1.004 287.504 1.166
202206 0.369 296.311 0.416
202209 -0.246 296.808 -0.277
202212 0.648 296.797 0.729
202303 -0.327 301.836 -0.362
202306 -1.091 305.109 -1.194
202309 -2.023 307.789 -2.195
202312 -2.243 306.746 -2.442
202403 -3.129 312.332 -3.346
202406 0.233 314.175 0.248
202409 2.703 315.301 2.863
202412 1.591 315.605 1.683
202503 0.545 319.799 0.569
202506 5.920 322.561 6.129
202509 4.448 324.800 4.573
202512 3.449 324.054 3.554
202603 3.255 330.213 3.292
202606 3.470 333.952 3.470

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Insmed (INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $120.00 is trading 44.6% below its estimated GF Value™ of $216.47. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for INSM:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $216.47 vs. price of $120.00 (44.6% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
69GF Score

Get the complete analysis for INSM

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$120.00
Price
$216.47
GF Value